This report provides comprehensive information on the therapeutic development for Herpes Zoster (Shingles), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Zoster (Shingles) and special features on late-stage and discontinued projects. http://www.researchmoz.us/herpes-zoster-shingles-pipeline-review-h1-2015-report.html

1. Herpes Zoster (Shingles) - Pipeline Review, H1 2015
Global Markets Directs, Herpes Zoster (Shingles) Pipeline Review, H1 2015, provides an overview of the Herpes Zoster (Shingles)s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Herpes Zoster (Shingles), complete with comparative analysis at various
stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and
featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Zoster (Shingles) and special features on
late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built
using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and
featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug
profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the
latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that
the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by
identifying new targets and MOAs to produce first-in-class and best-in-class products.
Scope
The report provides a snapshot of the global therapeutic landscape of Herpes Zoster (Shingles) The report reviews key pipeline products under drug profile
section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities The report reviews key
players involved in the therapeutics development for Herpes Zoster (Shingles) and enlists all their major and minor projects The report summarizes all the
dormant and discontinued pipeline projects A review of the Herpes Zoster (Shingles) products under development by companies and universities/research
institutes based on information derived from company and industry-specific sources Pipeline products coverage based on various stages of development ranging
from pre-registration till discovery and undisclosed stages A detailed assessment of monotherapy and combination therapy pipeline projects Coverage of the
Herpes Zoster (Shingles) pipeline on the basis of target, MoA, route of administration and molecule type Latest news and deals relating related to pipeline
products
Reasons to buy
Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies Identify emerging players
with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage Develop strategic initiatives by understanding the
focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Herpes Zoster (Shingles) Plan
mergers and acquisitions effectively by identifying key players of the most promising pipeline Devise corrective measures for pipeline projects by understanding
Herpes Zoster (Shingles) pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying
prospective partners with the most attractive projects to enhance and expand business potential and scope Modify the therapeutic portfolio by identifying
discontinued projects and understanding the factors that drove them from pipeline
table Of Contents
table Of Contents 2
list Of Tables 4
list Of Figures 5
introduction 6
global Markets Direct Report Coverage 6
herpes Zoster (shingles) Overview 7
therapeutics Development 8
pipeline Products For Herpes Zoster (shingles) - Overview 8
pipeline Products For Herpes Zoster (shingles) - Comparative Analysis 9
herpes Zoster (shingles) - Therapeutics Under Development By Companies 10
herpes Zoster (shingles) - Pipeline Products Glance 11
late Stage Products 11
clinical Stage Products 12
early Stage Products 13
unknown Stage Products 14
herpes Zoster (shingles) - Products Under Development By Companies 15
herpes Zoster (shingles) - Companies Involved In Therapeutics Development 16
astellas Pharma Inc. 16
epiphany Biosciences, Inc. 17
foamix Pharmaceuticals Ltd. 18
glaxosmithkline Plc 19
merck & Co., Inc. 20
nal Pharmaceuticals Ltd. 21
spider Biotech 22
herpes Zoster (shingles) - Therapeutics Assessment 23
assessment By Monotherapy Products 23
assessment By Target 24
assessment By Mechanism Of Action 26
Herpes Zoster (Shingles) - Pipeline Review, H1 2015

2. assessment By Route Of Administration 28
assessment By Molecule Type 30
drug Profiles 32
acyclovir - Drug Profile 32
product Description 32
mechanism Of Action 32
r&d Progress 32
amenamevir - Drug Profile 33
product Description 33
mechanism Of Action 33
r&d Progress 33
fv-100 - Drug Profile 34
product Description 34
mechanism Of Action 34
r&d Progress 34
gsk-1437173a - Drug Profile 36
product Description 36
mechanism Of Action 36
r&d Progress 36
nal-3221 - Drug Profile 38
product Description 38
mechanism Of Action 38
r&d Progress 38
nal-3223 - Drug Profile 39
product Description 39
mechanism Of Action 39
r&d Progress 39
sb105-a10 - Drug Profile 40
product Description 40
mechanism Of Action 40
r&d Progress 40
v-212 - Drug Profile 42
product Description 42
mechanism Of Action 42
r&d Progress 42
valomaciclovir Stearate - Drug Profile 44
product Description 44
mechanism Of Action 44
r&d Progress 44
herpes Zoster (shingles) - Recent Pipeline Updates 46
herpes Zoster (shingles) - Dormant Projects 50
herpes Zoster (shingles) - Discontinued Products 51
herpes Zoster (shingles) - Product Development Milestones 52
featured News & Press Releases 52
mar 09, 2015: Contravir Pharmaceuticals To Initiate Pivotal Phase 3 Study Of Fv-100 For Prevention Of Shingles-associated Phn 52
dec 18, 2014: Pivotal Phase Iii Study Of Gsk Shingles Candidate Vaccine Meets Its Primary Endpoint 52
dec 18, 2014: Positive Outcome Of Phase 3 Study Of Gsk Shingles Vaccine Containing Agenus Adjuvant 53
dec 09, 2014: Contravir Pharmaceuticals Initiates Pharmacokinetic Study Of Lead Antiviral Fv-100 For Treating Shingles 53
oct 16, 2014: Contravir Pharmaceuticals Selects Pharmaceutical Product Development To Manage Phase 2b Study Of Lead Antiviral Fv-100 For Treating
Shingles 54
apr 09, 2013: Zoster Vaccine Effective Against Incident Herpes Zoster And Post-herpetic Neuralgia In Older Us Population, Cohort Study Finds 54
jul 18, 2012: Agenus Annnounces Intiation Of Phase Iii Clinical Trial Of Gsk's Herpes Zoster Vaccine Candidate In Immunocompromised Patients 56
jun 05, 2012: Kaiser Permanente Study Shows Gsk's Zoster Lowers Short-term Risk Of Shingles Recurrence 57
dec 13, 2010: Inhibitex Reports Promising Top-line Results From Phase Ii Shingles Trial With Fv-100 58
oct 15, 2010: Inhibitex Completes Enrollment In Phase Ii Clinical Trial Of Fv-100 In Shingles Patients 59
appendix 60
methodology 60
coverage 60
secondary Research 60
primary Research 60
expert Panel Validation 60
contact Us 60
disclaimer 61
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your
research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and
Herpes Zoster (Shingles) - Pipeline Review, H1 2015

3. across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an
informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
Contact:
Sales Team,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Herpes Zoster (Shingles) - Pipeline Review, H1 2015